X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.165 ^USD	+3.10%		-7.54%	+38.94%

Mar. 21	Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Mar. 21	X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 21, 2024 at 07:43 am EDT

X4 Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 19.13 million compared to USD 29.1 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.29 a year ago.

Latest news about X4 Pharmaceuticals, Inc.

Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
North American Morning Briefing : Investors -2-	Mar. 21	DJ
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3	Dec. 12	MT
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	Dec. 09	CI
Transcript : X4 Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing	Nov. 03	MT
X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing	Nov. 03	MT
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome	23-10-31	CI
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors	23-10-18	CI
Transcript : X4 Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 07:30 AM	23-09-13
X4 Pharmaceuticals Submits NDA to FDA for Mavorixafor to Treat WHIM Syndrome	23-09-05	MT
X4 Pharmaceuticals Announces Submission of New Drug Application to U.S. Fda for Mavorixafor in Whim Syndrome	23-09-05	CI
B. Riley Trims X4 Pharmaceuticals' Price Target to $3 From $4, Keeps Buy Rating	23-08-30	MT
X4 Pharmaceuticals Files $300 Million Mixed Shelf	23-08-14	MT
Transcript : X4 Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ
X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer	23-08-09	CI
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital	23-08-03	CI
X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding	23-08-02	CI
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell Small Cap Comp Value Index	23-06-23	CI

Chart X4 Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.165 USD

Average target price

3.554 USD

Spread / Average Target

+205.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
X4 PHARMACEUTICALS, INC.	+38.94%	196M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs